Literature DB >> 15618347

NO and NO-independent mechanisms mediate ETB receptor buffering of ET-1-induced renal vasoconstriction in the rat.

Armin Just1, Andrea J M Olson, John R Falck, William J Arendshorst.   

Abstract

Vascular endothelin (ET) type B (ET(B)) receptors exert dilator and constrictor actions in a complex interaction with ET(A) receptors. We aimed to clarify the presence and relative importance of nitric oxide (NO) and other mechanisms underlying the dilator effects of ET(B) receptors in rat kidneys. Complete inhibition of NO production with Nomega-nitro-L-arginine methyl ester (L-NAME, 25 mg/kg iv) enhanced the renal vasoconstriction elicited by ET-1 injected into the renal artery from -15 to -30%. Additional infusion of the NO donor nitroprusside (NP) into the renal artery did not reverse this effect (-29%) but effectively buffered ANG II-mediated vasoconstriction. Similarly, ET-1 responses were enhanced after a smaller intrarenal dose of L-NAME (-22 vs. -15%) and were unaffected by subsequent NP infusion (-21%). These results indicate that the responsiveness to ET-1 is buffered by ET(B) receptor-stimulated phasic release of NO, rather than its static mean level. Infusion of the ET(B) receptor antagonist BQ-788 into the renal artery further enhanced the ET-1 constrictor response to NP+L-NAME (-92 vs. -49%), revealing an NO-independent dilator component. In controls, vasoconstriction to ET-1 was unaffected by vehicle (-27 vs. -20%) and markedly enhanced by BQ-788 (-70%). The same pattern was observed when indomethacin (Indo) was used to inhibit cyclooxygenase (-20% for control, -22% with Indo, and -56% with ET(B) antagonist) or methylsulfonyl-6-(2-propargyloxyphenyl)-hexanamide (MS-PPOH) or miconazole+Indo was used to inhibit epoxygenase alone (-10% for control, -11% with MS-PPOH, and -35% with ET(B) antagonist) or in combination (-14% for control, -20% with Indo + miconazole, and -43% with ET(B) antagonist). We conclude that phasic release of NO, but not its static level, mediates part of the dilator effect of ET(B) receptors and that an NO-independent mechanism, distinct from prostanoids and epoxyeicosatetraenoic acids, perhaps ET(B) receptor clearance of ET-1, plays a major buffering role.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15618347     DOI: 10.1152/ajpregu.00550.2004

Source DB:  PubMed          Journal:  Am J Physiol Regul Integr Comp Physiol        ISSN: 0363-6119            Impact factor:   3.619


  6 in total

Review 1.  Renal autoregulation in health and disease.

Authors:  Mattias Carlström; Christopher S Wilcox; William J Arendshorst
Journal:  Physiol Rev       Date:  2015-04       Impact factor: 37.312

2.  Constriction of rat extra-splenic veins to lipopolysaccharide involves endothelin-1.

Authors:  Arnaud Mansart; Lewis J Ruff; Mark P Ariaans; Jonathan J Ross; Charles S Reilly; Nicola J Brown; Susan Kaufman; Zoë L S Brookes
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2010-04-16       Impact factor: 3.000

Review 3.  Endothelin and the renal microcirculation.

Authors:  Zhengrong Guan; Justin P VanBeusecum; Edward W Inscho
Journal:  Semin Nephrol       Date:  2015-03       Impact factor: 5.299

4.  ADP-ribosyl cyclase and ryanodine receptors mediate endothelin ETA and ETB receptor-induced renal vasoconstriction in vivo.

Authors:  Tiffany L Thai; William J Arendshorst
Journal:  Am J Physiol Renal Physiol       Date:  2008-06-04

5.  Modulation of the myogenic mechanism: concordant effects of NO synthesis inhibition and O2- dismutation on renal autoregulation in the time and frequency domains.

Authors:  Nicholas G Moss; Tayler K Gentle; William J Arendshorst
Journal:  Am J Physiol Renal Physiol       Date:  2016-01-28

6.  Low-Dose Aspirin Treatment Attenuates Male Rat Salt-Sensitive Hypertension via Platelet Cyclooxygenase 1 and Complement Cascade Pathway.

Authors:  Xiaoliang Jiang; Xue Liu; Xing Liu; Xianxian Wu; Pedro A Jose; Min Liu; Zhiwei Yang
Journal:  J Am Heart Assoc       Date:  2019-12-19       Impact factor: 5.501

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.